What is WO2003077914A1 related to?
Patent application WO2003077914A1 pertains to a method for treating cancers, specifically melanomas, using a combination of certain kinase inhibitors, including binimetinib [1]. The patent also covers pharmaceutical compositions and their use in treating such conditions [1]. Binimetinib, also known as MEK162 or ARRY-162, is a selective inhibitor of MEK1 and MEK2 enzymes [2].
When does the binimetinib patent protection expire?
The original patent application WO2003077914A1 was filed on March 12, 2003 [1]. Patent protection timelines are complex and depend on various factors including national filings, granted patents, and potential extensions. DrugPatentWatch.com provides detailed patent information and expiration dates for pharmaceuticals like binimetinib [3].
How does binimetinib work?
Binimetinib functions by inhibiting MEK1 and MEK2, which are key components of the RAS/RAF/MEK/ERK signaling pathway. This pathway is frequently dysregulated in various cancers, leading to uncontrolled cell growth and proliferation [2]. By blocking MEK, binimetinib disrupts this signaling cascade, thereby inhibiting tumor cell growth [2].
What are the clinical applications of binimetinib?
Binimetinib has been investigated and approved for the treatment of certain types of cancer. It is approved in combination with encorafenib for patients with BRAF V600E or BRAF V600K mutant unresectable or metastatic melanoma [4]. This combination targets both the BRAF and MEK pathways, offering a dual blockade against tumor growth [4]. Clinical trials have also explored its use in other BRAF-mutated solid tumors [2].
Who developed binimetinib?
Binimetinib was developed by Array BioPharma, which was later acquired by Pfizer [5].
What are the risks or side effects associated with binimetinib?
Common side effects reported with binimetinib, particularly in combination therapy, include gastrointestinal issues like diarrhea, nausea, and vomiting, as well as fatigue, rash, and elevated liver enzymes [4]. More serious adverse events can also occur, and patients should discuss potential risks with their healthcare providers [4].
Are there alternative treatments for BRAF-mutated melanoma?
Yes, there are alternative treatment options for BRAF-mutated melanoma. These include other targeted therapy combinations, such as dabrafenib and trametinib, as well as immunotherapy [6]. The choice of treatment depends on the individual patient's disease characteristics and overall health [6].
Sources:
1. https://patents.google.com/patent/WO2003077914A1/en
2. https://www.drugpatentwatch.com/drugs/binimetinib
3. https://www.drugpatentwatch.com/
4. https://www.fda.gov/drugs/drug-approvals/braftovi-encorafenib-and-mektovi-binimetinib-combination-therapy-fda-approves-new-treatment-option-patients
5. https://www.pfizer.com/news/press-release/press-release-detail/arraybiopharmaannouncescompletionofitsacquisitionbypfizer
6. https://www.cancer.gov/types/skin/treatment/melanoma-treatment-pdq